Cross-Sector entity
Evercore is most often covered alongside Royal Bank of Canada, which appears in 7 of these 20 stories. The 40-day window averages about 3.5 stories each week. The busiest single day carried 4. earnings accounts for 4 of the 20 tracked stories, while 9 other categories carry the remainder.
21 verified stories tracked
Last mentioned: 1d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 5 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Evercore is most often covered alongside Royal Bank of Canada, which appears in 7 of these 20 stories. The 40-day window averages about 3.5 stories each week. The busiest single day carried 4. earnings accounts for 4 of the 20 tracked stories, while 9 other categories carry the remainder. We currently track 20 Cross-Sector stories that mention Evercore, published between July 15, 2026 and August 23, 2026. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Evercore. Shared-story counts are live from our verified record — not editorial picks.
Press Release Distribution
Company issues PRNewswire release summarizing the summit highlights.
Evercore Summit Presentation
Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Q2 2026 earnings release for Lineage and Magnite
Both companies reported earnings after market close: Lineage EPS $0.76 (beat by $0.98), Magnite EPS $0.26 (beat by $0.01).
ZVIA reports Q2 results
Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
Weiss reiterates buy on STAG; Baird sets $138 target
Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
STAG reports Q2 earnings miss
Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
Lineage dividend payment date
Lineage paid quarterly dividend of $0.5325 to shareholders of record on June 30.
Wells Fargo raises Magnite target
Wells Fargo increased price objective from $15 to $21, maintained Equal Weight.
Weiss Ratings upgrades ZVIA within sell range
Weiss Ratings raised shares of Zevia PBC from a sell (e+) rating to a sell (d-) rating.
Barclays raises STAG target but stays Underweight
Barclays boosted its price objective on Stag Industrial from $38.00 to $41.00 and maintained an underweight rating.
Lineage dividend record date
Record date for Lineage's quarterly dividend of $0.5325 per share.
Wells Fargo cuts STAG target to $40
Wells Fargo & Company lowered its target price on Stag Industrial from $41.00 to $40.00 and set an equal weight rating.
RBC reaffirms Magnite Outperform
Royal Bank of Canada reiterated an Outperform rating on Magnite shares.
Caisse sells 2.15M ZVIA shares
Major shareholder Caisse de dépôt et placement du Québec sold 2,150,000 shares of Zevia PBC at an average price of $1.90, totaling $4.085 million, reducing its stake by 15.87%.
Weiss Ratings upgrades Magnite
Weiss Ratings raised Magnite from 'hold (c-)' to 'hold (c)' rating.
Evercore and Scotiabank issue Magnite updates
Evercore reiterated Outperform with $21 target; Scotiabank raised target from $16 to $17, Sector Outperform.
Evercore reiterates Outperform on STAG
Evercore reissued an outperform rating and set a $44.00 price objective on Stag Industrial.
For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Source: prnewswire.com · manilatimes.net
Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Source: tickerreport.com · dailypolitical.com
HSBC's increased holding and 91% institutional ownership underline confidence in TJX's off‑price model. With analysts projecting a $190 price target, the retailer's brick-and-mortar treasure-hunt experience continues to attract both consumer and institutional capital, defying e-commerce pressures.
Source: dailypolitical.com · tickerreport.com
Alexandria Real Estate Equities reported Q2 revenue of $662.78M, beating estimates, but a sharp EPS miss and cautious analyst outlook raise questions about how PropTech investments in smart labs and energy management will weather a softening biotech leasing market. The REIT’s guidance of $6.35-$6.45 EPS anchors expectations for rent growth and operational efficiency gains.
Alexandria Real Estate Equities shares climbed 3.2% to $53.08 after Q2 revenue of $662.78M beat estimates, even as EPS missed by $0.52. The FY 2026 EPS guidance of $6.35-$6.45 provides a stalwart midpoint against a choppy analyst landscape, while a 5.4% dividend yield offers a cushion for income investors.
As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Source: dailypolitical.com · tickerreport.com
Lineage, a leading cold storage REIT, reported a massive EPS beat but negligible revenue growth, highlighting softness in food logistics demand. The negative dividend payout ratio raises sustainability questions for income-focused investors.
Magnite's Q2 adtech earnings surpassed estimates, driven by 11.3% revenue growth, robust net margins of 21.96%, and a strong analyst consensus. The stock dip belies underlying platform health and CTV momentum.
Two disparate earnings beats: Lineage posted a massive $0.98 EPS surprise but carries negative margins, while Magnite delivered a smaller beat with solid profitability. The comparison reveals risks in chasing headline beats and highlights valuation disconnects.
Source: themarketsdaily.com · tickerreport.com
Apollo Global Management’s £5.7 billion all-cash offer for easyJet, backed by the founder, highlights private equity’s hunger for discounted London-listed assets. With Castlelake out, the path is clearer, but EU ownership rules pose a significant regulatory wrinkle.
Source: shanghainews.net · calcuttanews.net
Apollo Global’s £5.7 billion all-cash bid for easyJet underscores private equity’s appetite for discounted UK assets. The deal triggers EU ownership scrutiny, while Castlelake’s withdrawal signals competitive dynamics in large-cap takeovers.
Source: parisguardian.com · haitisun.com
CBRE Group's above-consensus EPS guidance underscores the commercial real estate sector's momentum, driven by technology-driven services. For PropTech startups and investors, it signals growing client spending on smart buildings, data analytics, and digital brokerage platforms.
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
CPKC's Q2 earnings beat, with revenue up 12.6% to $2.93 billion, highlights robust cross-border rail demand. For supply chain professionals, the performance reflects strong trade flows and network integration benefits post-merger.
Canadian Pacific Kansas City posted a $0.03 EPS beat and 12.6% revenue growth, maintaining strong margins. With a consensus Buy rating and price targets as high as $105, the stock offers a defensive growth story for investors.
Source: themarketsdaily.com · dailypolitical.com
Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10, surpassing consensus, signals resilience in manufactured housing REITs. The update, alongside a massive Q2 loss, highlights the need for operational technology to improve asset performance and expense control.
Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10 beat the $6.93 consensus, but shares fell 0.4% on heavy volume as revenue guidance was absent. Analyst targets average $140.05, suggesting 15% upside from $121.30 despite recent price target cuts.
Source: MarketBeat · themarketsdaily.com
Morgan Stanley lowered its BlackRock (BLK) price target to $1,383 while maintaining Overweight, implying a 34% gain. The consensus remains Moderate Buy with an average target of $1,270.72. Diverging analyst revisions signal both caution and opportunity for the asset management giant.
Source: Zolmax · Markets Daily
